MeMed

Executive Summary

MeMed is an Israeli med-tech company specializing in rapid host-immune response diagnostics for infectious and inflammatory diseases. Its flagship product, MeMed BV, is a point-of-care test that distinguishes bacterial from viral infections within 15 minutes by measuring multiple proteins via a machine-learning-driven multiplex immunoassay. This addresses a critical unmet need in antimicrobial stewardship, helping to reduce inappropriate antibiotic prescriptions. The company also offers the MeMed Key platform for precise protein measurement at the point of care. With $120 million raised and a commercial-stage status, MeMed has established a strong foothold in the diagnostics market. The company's technology is backed by clinical evidence and aims to improve patient outcomes while combating antimicrobial resistance. As a private company with 200-500 employees, MeMed continues to expand its commercial footprint and develop new applications for its platform.

Upcoming Catalysts (preview)

• Q2 2026FDA Clearance for Pediatric Indication70% success
• Q3 2026Major Distribution Partnership in EU65% success
• Q4 2026New Clinical Data Supporting Sepsis Detection60% success